Lapatinib for the treatment of breast cancer in the people's Republic of China

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1367-1373

  Wang, Hongjiang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; HER2 positive; Lapatinib; Molecular targeting therapy

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PLACEBO; TRASTUZUMAB;

ADJUVANT THERAPY; ADVANCED CANCER; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RESISTANCE; CANCER STAGING; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CHINA; DRUG APPROVAL; DRUG INFORMATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SYMPTOM;

EID: 84905592700     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S60586     Document Type: Review

References (59)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131(1): 18-43.
3. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009; 14(4): 320-368.
4. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008; 9(1): 23-28.
5. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004; 22(6): 1063-1070.
6. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006; 11(4): 318-324.
7. Cameron D. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Clin Adv Hematol Oncol. 2007; 5(6): 456-458.
8. Spector NL, Xia W, Burris H 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005; 23(11): 2502-2512.
9. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002; 21(41): 6255-6263.
10. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3): 1630-1639.
11. Polier S, Samant RS, Clarke PA, et al. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol. 2013; 9(5): 307-312.
12. Rexer BN, Ham AJ, Rinehart C, et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. 2011; 30(40): 4163-4174.
13. Lee YY, Kim HP, Kang MJ, et al. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp Mol Med. 2013; 45: e64.
14. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001; 1(2): 85-94.
15. Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 2006; 40(2): 261-269.
16. Satoh T, Xu RH, Chung HC, et al. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN-A Randomized, Phase III Study. J Clin Oncol. 2014; 32(19): 2039-2049.
17. Gandhi MD, Agulnik M. Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. Onco Targets Ther. 2014; 7: 245-251.
18. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008; 36(4): 695-701.
19. Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos. 2009; 37(2): 439-442.
20. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007; 25(16): 2306-2312.
21. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011; 11(5): 352-363.
22. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012; 29(3): 770-781.
23. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008; 100(15): 1092-1103.
24. Kaplan MA, Ertugrul H, Firat U, et al. Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab. Breast Cancer. Epub January 3, 2014.
25. Lin NU, Freedman RA, Ramakrishna N, et al. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013; 142(2): 405-414.
26. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004; 64(18): 6652-6659.
27. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001; 61(19): 7196-7203.
28. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011; 10(2): 111-126.
29. Fedele C, Riccio G, Coppola C, et al. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat. 2012; 133(2): 511-521.
30. FDA. Tykerb (Lapatinib) FDA NDA Pharmacology Review [webpage on the Internet]. 2008: Available from: http:// www. accessdata. fda. gov/drugsatfda_docs/nda/2007/022059s000TOC. cfm. Accessed on July 16, 2014.
31. Dogan E, Yorgun H, Petekkaya I, et al. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience. Med Oncol. 2012; 29(5): 3232-3239.
32. Spector NL, Yarden Y, Smith B, et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A. 2007; 104(25): 10607-10612.
33. Tykerb® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
34. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005; 65(1): 18-25.
35. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009; 28(6): 803-814.
36. Li Z, Chang T, Shi l. [Compensatory activation of estrogen receptor alpha signaling in acquired resistance to lapatinib of HER-2 overexpressing/ER alpha-positive breast cancer cells]. Academic Journal of Second Military Medical University. 2013; 34: 616-622. Chinese.
37. Zhao L. Wnt/β-catenin[Effect of Wnt/β-catenin pathway on lapatinib resistance in breast cancer]. Jiangsu Medical Journal. 2013; 39: 2242-2249. Chinese.
38. Zhang H, Mao X, Lin Z, et al. [Mechanism of Her-2 overexpressed breast cancer cell apoptosis induced by lapatinib]. Shandong Medicine Journal. 2011; 51: 1-3. Chinese.
39. Schluter B, Gerhards R, Strumberg D, Voigtmann R. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010; 136(9): 1389-1400.
40. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26): 2733-2743.
41. Goss PE, Smith IE, O'Shaughnessy J, et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(1): 88-96.
42. Chong HY, Taib NA, Rampal S, et al. Treatment options for locally advanced breast cancer-experience in an Asian tertiary hospital. Asian Pac J Cancer Prev. 2010; 11(4): 913-917.
43. Lal S, Wong ZW, Jada SR, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007; 8(6): 567-575.
44. Han C, You J, Jing F, et al. [Therapeutic effect of lapatinib on HER-2 positive advanced breast cancer]. J Chinese PLA Postgrad Med Sch. 2013; 4: 325-326. Chinese.
45. Xu BH, Jiang ZF, Chua D, et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer. 2011; 30(5): 327-335.
46. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008; 112(3): 533-543.
47. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2): 123-132.
48. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10): 947-957.
49. Xu B. [Therapeutic criteria and strategy in advanced breast cancer]. China Medical Herald. 2010; 7: 6-8. Chinese.
50. Jiang Z, Shao Z, Xu B. [National guidline for management of human epidermal growth factor receptor 2 positive breast cancer]. Chin J Oncol. 2010; 32: 158-160. Chinese.
51. Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009; 117(3): 577-589.
52. Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009; 16(10): 2705-2710.
53. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 2004; 23(3): 646-653.
54. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007; 6(2): 667-674.
55. Xia W, Husain I, Liu L, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007; 67(3): 1170-1175.
56. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5): 269-280.
57. Ma F, Li Q, Li H, et al. [Clinical evaluation of trastuzumab in the treatment of lapatinib-resistant breast cancer] Zhong Hua Yi Xue Zhong Liu Xue Hui Lun Wen Hui Bian. 2011; 7: 6-8. Chinese.
58. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006; 11(10): 1047-1057.
59. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009; 15(4): 1452-1459.